

Alliance A091305
Update #3
Version Date 5/31/2018

NCI Community Oncology Research Program – Kansas City (NCORP-KC)

Study Title for Study Participants: Testing the addition of efatutazone to usual chemotherapy in advanced anaplastic thyroid cancer

Official Study Title for Internet Search on <http://www.ClinicalTrials.gov>: A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer

What is the usual approach to my anaplastic thyroid cancer?

You are being asked to take part in this study because you have anaplastic thyroid cancer which cannot be removed with surgery or has spread to other areas of the body. People who are not in a study are usually treated with radiation, and/or medications. Combinations of medications can be used and your doctor can explain which may be best for you. These treatments can reduce symptoms and may stop the tumor from growing. Your type of cancer frequently spreads to other parts of the body (lungs, bones, liver, etc.), and so chemotherapy may be given.

What are my other choices if I do not take part in this study?

If you decide not to take part in this study, you have other choices. For example:

- you may choose to have the usual approach described above
- you may choose to take part in a different study, if one is available
- or you may choose not to be treated for cancer but you may want to receive comfort care to relieve symptoms.

Why is this study being done?

Despite the aggressive treatment for anaplastic thyroid cancer that we described above, only one in five (20%) of patients is alive one year after their cancer is detected. Therefore, newer drugs are needed for your disease.

The purpose of this study is to compare any good and bad effects of using efatutazone along with the usual chemotherapy. The addition of efatutazone to the usual chemotherapy (paclitaxel) could shrink your cancer but it could also cause side effects. This study will allow the

Approval Date 7/25/2018 to 6/13/2019

Assurance#: FWA00003582


Alliance A091305
Update #3
Version Date 5/31/2018

researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the study drug should increase life by four months or more compared to the usual approach. There will be about 20 people taking part in this study.

What are the study groups?

This study has one study groups. All patients will receive usual chemotherapy with paclitaxel (given intravenously every 21 days) and the study drug (efatutazone, a pill taken twice daily by mouth). Patients participating in the study will be asked to keep a patient medication diary for efatutazone, daily, during each treatment cycle.

Another way to find out what will happen to you during this study is to read the chart below. Start reading at the left side and read across to the right, following the lines and arrows.



How long will I be in this study?

You will receive the study drug(s) as long as your tumor responds to the treatment and you do not have severe side effects. After you finish study treatment, your doctor will continue to watch you for side effects and follow your condition.

What extra tests and procedures will I have if I take part in this study?

Most of the exams, tests, and procedures you will have are part of the usual approach for your cancer. However, there are some extra tests, and/or procedures that you will need to have if you take part in this study.

Neither you nor your health care plan/insurance carrier will be billed for the collection of the tumor tissues that will be used for this study.

Approval Date 7/25/2018 to 6/13/2019

Assurance#: FWA00003582

Alliance A091305
Update #3
Version Date 5/31/2018

Before you begin the study, you will undergo labwork and imaging tests that are standard of care for your cancer.

If the exams, tests, and procedures show that you can take part in the study, and you choose to take part, then you will need the following:

During the study:

- Blood tests every 3 weeks while you receive treatment on the study
- Imaging of your tumor will be done every 6 weeks while you receive treatment on the study, and every 8 weeks thereafter, until your cancer progresses
- You will need to see your physician for a physical exam every 3 weeks while you receive treatment on the study

What possible risks can I expect from taking part in this study?

If you choose to take part in this study, there is a risk that:

- You may lose time at work or home and spend more time in the hospital or doctor's office than usual
- The study drug(s)/study approach may not be better, and could possibly be worse, than the usual approach for your cancer.

The drugs used in this study may affect how different parts of your body work such as your liver, kidneys, heart, and blood. The study doctor will be testing your blood and will let you know if changes occur that may affect your health.

There is also a risk that you could have side effects from the study drugs.

Here are important points about side effects:

- The study doctors do not know who will or will not have side effects.
- Some side effects may go away soon, some may last a long time, or some may never go away.
- Some side effects may interfere with your ability to have children.
- Some side effects may be serious and may even result in death.

Here are important points about how you and the study doctor can make side effects less of a problem:

- Tell the study doctor if you notice or feel anything different so they can see if you are having a side effect.
- The study doctor may be able to treat some side effects.
- The study doctor may adjust the study drugs to try to reduce side effects.

Approval Date 7/25/2018 to 6/13/2019

Assurance#: FWA00003582

Alliance A091305
Update #3
Version Date 5/31/2018

The tables below show the most common and the most serious side effects that researchers know about. There might be other side effects that researchers do not yet know about. If important new side effects are found, the study doctor will discuss these with you.

Possible side effects of which is the usual approach for this type of cancer:

Possible Side Effects of Paclitaxel (Table Version Date: August 23, 2013)

COMMON, SOME MAY BE SERIOUS
In 100 people receiving Paclitaxel, more than 20 and up to 100 may have:
<ul style="list-style-type: none"> • Anemia which may cause tiredness, or may require blood transfusions • Infection, especially when white blood cell count is low • Diarrhea, nausea, vomiting • Sores in mouth which may cause difficulty swallowing • Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of breath, swelling of the face or throat • Bruising, bleeding • Pain • Muscle weakness • Numbness, tingling or pain of the arms and legs • Hair loss

OCCASIONAL, SOME MAY BE SERIOUS
In 100 people receiving Paclitaxel, from 4 to 20 may have:
<ul style="list-style-type: none"> • Abnormal heartbeat • Damage to the lungs which may cause shortness of breath • Blood clot which may cause swelling, pain, shortness of breath

RARE, AND SERIOUS
In 100 people receiving Paclitaxel, 3 or fewer may have:
<ul style="list-style-type: none"> • Heart attack or heart failure which may cause shortness of breath, swelling of ankles, and tiredness • A tear or a hole in the stomach which may cause belly pain or that may require surgery

In addition to side effects outlined above, people who are in Group 1 may also experience the possible side effects of efatutazone listed below.

Approval Date 7/25/2018 to 6/13/2019

Assurance#: FWA00003582

Alliance A091305
 Update #3
 Version Date 5/31/2018

Possible Side Effects of Efatutazone

COMMON, SOME MAY BE SERIOUS
In 100 people receiving Efatutazone, more than 20 and up to 100 may have:
<ul style="list-style-type: none"> • Weight gain • Swelling of the face, arms, and/or legs • Shortness of breath • Anemia which may cause tiredness, or may require blood transfusions • Fatigue
OCCASIONAL, SOME MAY BE SERIOUS
In 100 people receiving Efatutazone, from 4 to 20 may have:
<ul style="list-style-type: none"> • Dizziness • Increased heart rate
RARE, AND SERIOUS
In 100 people receiving Efatutazone 3 or fewer may have:
<ul style="list-style-type: none"> • Buildup of an abnormal amount of fluid around the heart • Buildup of an abnormal amount of fluid around the lungs

Let your study doctor know of any questions you have about possible side effects. You can ask the study doctor questions about side effects at any time.

Reproductive risks: You should not get pregnant, breastfeed, or father a baby while in this study. The drugs used in this study could be very damaging to an unborn baby. Check with the study doctor about what types of birth control, or pregnancy prevention, to use while in this study.

What possible benefits can I expect from taking part in this study?

It is not possible to know at this time if the study drug is better than the usual approach so this study may or may not help you. This study will help researchers learn things that will help people in the future.

Can I stop taking part in this study?

Yes. You can decide to stop at any time. If you decide to stop for any reason, it is important to let the study doctor know as soon as possible so you can stop safely. If you stop, you can decide whether or not to let the study doctor continue to provide your medical information to the organization running the study.

Approval Date 7/25/2018 to 6/13/2019

Assurance#: FWA00003582

Alliance A091305
Update #3
Version Date 5/31/2018

The study doctor will tell you about new information or changes in the study that may affect your health or your willingness to continue in the study.

The study doctor may take you out of the study:

- If your health changes and the study is no longer in your best interest
- If new information becomes available
- If you do not follow the study rules
- If the study is stopped by the sponsor, IRB or FDA.

What are my rights in this study?

Taking part in this study is your choice. No matter what decision you make, and even if your decision changes, there will be no penalty to you. You will not lose medical care or any legal rights.

For questions about your rights while in this study, call the _____ NCI Community Oncology Research Program – Kansas City Institutional Review Board at 913-948-5588.

What are the costs of taking part in this study?

The efatutazone will be supplied at no charge while you take part in this study. The cost of getting the paclitaxel ready and giving it to you is not paid by the study sponsor so you or your insurance company may have to pay for this. It is possible that the efatutazone may not continue to be supplied while you are on the study. Although not likely, if this occurs, your study doctor will talk to you about your options.

You and/or your health plan/insurance company will need to pay for all of the other costs of treating your cancer while in this study, including the cost of tests, procedures, or medicines to manage any side effects, unless you are told that certain tests are supplied at no charge. Before you decide to be in the study, you should check with your health plan or insurance company to find out exactly what they will pay for.

You will not be paid for taking part in this study.

What happens if I am injured or hurt because I took part in this study?

If you are injured or hurt as a result of taking part in this study and need medical treatment, please tell your study doctor. The study sponsors will not offer to pay for medical treatment for

Approval Date 7/25/2018 to 6/13/2019

Assurance#: FWA00003582

Alliance A091305
Update #3
Version Date 5/31/2018

injury. Your insurance company may not be willing to pay for study-related injury. If you have no insurance, you would be responsible for any costs.

If you feel this injury was a result of medical error, you keep all your legal rights to receive payment for this even though you are in a study.

Who will see my medical information?

Your privacy is very important to us and the researchers will make every effort to protect it. Your information may be given out if required by law. For example, certain states require doctors to report to health boards if they find a disease like tuberculosis. However, the researchers will do their best to make sure that any information that is released will not identify you. Some of your health information, and/or information about your specimen, from this study will be kept in a central database for research. Your name or contact information will not be put in the database.

There are organizations that may inspect your records. These organizations are required to make sure your information is kept private, unless required by law to provide information. Some of these organizations are:

- The study sponsor and any drug company supporting the study
- The Institutional Review Board, IRB, is a group of people who review the research with the goal of protecting the people who take part in the study.
- The Food and Drug Administration and the National Cancer Institute in the U.S., and similar ones if other countries are involved in the study.

Where can I get more information?

You may visit the NCI Web site at <http://cancer.gov/> for more information about studies or general information about cancer. You may also call the NCI Cancer Information Service to get the same information at: 1-800-4-CANCER (1-800-422-6237).

A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

Who can answer my questions about this study?

You can talk to the study doctor about any questions or concerns you have about this study or to report side effects or injuries. Contact the study doctor _____ (*insert name of study doctor[s]*) at _____ (*insert telephone number*).

Approval Date 7/25/2018 to 6/13/2019

Assurance#: FWA00003582

Alliance A091305
 Update #3
 Version Date 5/31/2018

ADDITIONAL STUDIES SECTION:

This section is about optional studies you can choose to take part in

This part of the consent form is about an optional study that you can choose to take part in. You will not get health benefits from this study. The researchers leading this optional study hope the results will help other people with cancer in the future.

The results will not be added to your medical records and you or your study doctor will not know the results.

You will not be billed for this optional study. You can still take part in the main study even if you say “no” to this study. If you sign up for but cannot complete this study for any reason, you can still take part in the main study.

Circle your choice of “yes” or “no” for each of the following studies.

Optional Sample Collections for Laboratory Studies and/or Biobanking for Possible Future Studies

Researchers are trying to learn more about cancer, diabetes, and other health problems. Much of this research is done using samples from your tissue, blood, urine, or other fluids. Through these studies, researchers hope to find new ways to prevent, detect, treat, or cure health problems.

Some of these studies may be about genes. Genes carry information about features that are found in you and in people who are related to you. Researchers are interested in the way that genes affect how your body responds to treatment.

If you choose to take part in this study, the study doctor for the main study would like to collect a sample of tissue from your previous biopsy or surgery for research on genes present in your tumor that may predict the likelihood of your responding to the study drugs.

If you choose to take part, a sample of tissue from your previous biopsy or surgery will be collected. The researchers ask your permission to store and use your samples and related health information (for example, your response to cancer treatment, results of study tests and medicines you are given) for medical research. Some of the research that may be done is unknown at this time. Storing samples for future studies is called “biobanking”. The Biobank is being run by the Alliance and supported by the National Cancer Institute.

WHAT IS INVOLVED?

If you agree to take part, here is what will happen next:

- 1) A sample from the tissue that was collected at the time of your biopsy or surgery will be sent to the Biobank.

Approval Date 7/25/2018 to 6/13/2019

Assurance#: FWA00003582

Alliance A091305
 Update #3
 Version Date 5/31/2018

- 2) Your sample and some related health information will be sent to a researcher for use in the study described above. Remaining samples may be stored in the Biobank, along with samples from other people who take part. The samples will be kept until they are used up.
- 3) Qualified researchers can submit a request to use the materials stored in the Biobank. A science committee at the clinical trials organization, and/or the National Cancer Institute, will review each request. There will also be an ethics review to ensure that the request is necessary and proper. Researchers will not be given your name or any other information that could directly identify you.
- 4) Neither you nor your study doctor will be notified when research will be conducted or given reports or other information about any research that is done using your samples.
- 5) Some of your genetic and health information may be placed in central databases that may be public, along with information from many other people. Information that could directly identify you will not be included.

WHAT ARE THE POSSIBLE RISKS?

- 1) There is a risk that someone could get access to the personal information in your medical records or other information researchers have stored about you.
- 2) There is a risk that someone could trace the information in a central database back to you. Even without your name or other identifiers, your genetic information is unique to you. The researchers believe the chance that someone will identify you is very small, but the risk may change in the future as people come up with new ways of tracing information.
- 3) In some cases, this information could be used to make it harder for you to get or keep a job or insurance. There are laws against the misuse of genetic information, but they may not give full protection. There can also be a risk in knowing genetic information. New health information about inherited traits that might affect you or your blood relatives could be found during a study. The researchers believe the chance these things will happen is very small, but cannot promise that they will not occur.

HOW WILL INFORMATION ABOUT ME BE KEPT PRIVATE?

Your privacy is very important to the researchers and they will make every effort to protect it. Here are just a few of the steps they will take:

- 1) When your sample(s) is sent to the researchers, no information identifying you (such as your name) will be sent. Samples will be identified by a unique code only.
- 2) The list that links the unique code to your name will be kept separate from your sample and health information. Any Biobank and Alliance staff with access to the list must sign an agreement to keep your identity confidential.
- 3) Researchers to whom Alliance sends your sample and information will not know who you are. They must also sign an agreement that they will not try to find out who you are.
- 4) Information that identifies you will not be given to anyone, unless required by law.

Approval Date 7/25/2018 to 6/13/2019

Assurance#: FWA00003582

Alliance A091305
Update #3
Version Date 5/31/2018

- 5) If research results are published, your name and other personal information will not be used.

WHAT ARE THE POSSIBLE BENEFITS?

The researchers, using the samples from you and others, might make discoveries that could help people in the future.

ARE THERE ANY COSTS OR PAYMENTS?

There are no costs to you or your insurance. You will not be paid for taking part. If any of the research leads to new tests, drugs, or other commercial products, you will not share in any profits.

WHAT IF I CHANGE MY MIND?

If you decide you no longer want your samples to be used, you can call the study doctor, _____, *(insert name of study doctor for main trial)* at _____ *(insert telephone number of study doctor for main trial)* who will let the researchers know. Then, any sample that remains in the bank will no longer be used and related health information will no longer be collected. Samples or related information that have already been given to or used by researchers will not be returned.

WHAT IF I HAVE MORE QUESTIONS?

If you have questions about the use of your samples for research, contact the study doctor, _____, *(insert name of study doctor for main trial)*, at _____ *(insert telephone number of study doctor for main trial)*.

Please circle your answer to show whether or not you would like to take part in each option:

SAMPLES FOR THE LABORATORY STUDIES:

I agree to have my specimen collected and I agree that my specimen sample(s) and related information may be used for the laboratory study(ies) described above.

YES NO

SAMPLES FOR FUTURE RESEARCH STUDIES:

My samples and related information may be kept in a Biobank for use in future health research.

YES NO

Approval Date 7/25/2018 to 6/13/2019
Assurance#: FWA00003582

Alliance A091305
Update #3
Version Date 5/31/2018

I agree that my study doctor, or their representative, may contact me or my physician to see if I wish to participate in other research in the future.

YES NO

This is the end of the section about optional studies.

Release

By signing this form you authorize NCORP-KC to access and obtain information that is required for the study. This may include your medical records, labs, radiologic films and reports and pathology specimens. This authorization to disclose your medical records shall not expire, even upon death, unless specifically revoked in writing by you.

You will get a copy of this form. If you want more information about this study, ask your study doctor.

My Signature Agreeing to Take Part in the Main Study

I have read this consent form or had it read to me. I have discussed it with the study doctor and my questions have been answered. I will be given a signed copy of this form. I agree to take part in the main study and any additional studies where I circled 'yes'.

Participant _____

Participant's signature _____

Date of signature _____

Person Obtaining Consent _____

Person Obtaining Consent Signature _____

Date of Signature _____

Approval Date 7/25/2018 to 6/13/2019
Assurance#: FWA00003582